SAN DIEGO, Nov. 17, 2014 /PRNewswire/ -- Further evidence that stimulating mitochondrial function results in improved markers of renal and cardiovascular dysfunction and that such markers, incorporated by ClinMet Inc. in a proprietary urine metabolomics profile, can help monitor renal function and predict response to drug therapies was presented over the weekend at Kidney Week 2014.
"Studies in both animals and humans have shown that reduced mitochondrial function appears to play a critical role in the progression of chronic kidney disease (CKD), as well as cardiovascular complications of diabetes. Moreover, findings suggest that drugs that restore mitochondrial superoxide levels can protect against further disease progression," said ClinMet scientific founder, Kumar Sharma, M.D., F.A.H.A. Professor of Medicine and the Director of Center for Renal Translational Medicine and the Institute of Metabolomic Medicine at the University of California, San Diego. "This week we have presented further validation for a novel group of urine metabolites related to mitochondrial function that are reduced in diabetics with decreased renal function, but not in individuals without kidney disease. New clinical studies have now shown that novel drugs that may be effective in this population increase the reduced metabolite levels towards non-CKD levels, possibly reflecting a stabilization of mitochondrial function."
A variety of oral and poster presentations by Dr. Sharma, ClinMet scientists and their academic collaborators and corporate partners were presented during the annual scientific meeting of the American Association of Nephrology, which was held from November 11 - 16 in Philadelphia, PA.
Dr. Sharma noted that the ClinMet metabolomics panel may provide the means for companies not only to stratify patients for clinical trials of potential therapeutics for diabetic kidney disease, but may also aid in related drug discovery by helping to predict the efficacy of potential therapeutics in this population. The new data is strongly supportive of this concept.
"Quantitative metabolomics studies offer a useful approach for more accurately understanding drug activity in the discovery and development of new therapies for diabetes and its related complications including kidney disease and cardiovascular conditions," said Shoba Sharma, ClinMet co-founder and Chief Operating Officer. "ClinMet's technological proficiency in metabolomics combined with our translational medicine expertise in the field of diabetes and kidney disease make our drug discovery platform and services unique in the industry."
About ClinMet Inc.
ClinMet Inc., founded in 2011, is a privately held company based in San Diego, CA that provides pharmaceutical companies with clinically relevant insights and actionable information about drug efficacy, safety and mechanism of action using its proprietary urine metabolomics biomarker platform for diabetes, kidney disease, obesity and cardiovascular disease. ClinMet applies its unique combination of in-depth clinical insights, proprietary metabolomics expertise, and computational know-how to improve the speed and success rate of drug development. The company helps drug developers to efficiently transform promising compounds into safe and effective medicines and to effectively develop and implement their companion diagnostics strategy. For more information, please visit the ClinMet website at http://www.clinmet.com.
SOURCE ClinMet Inc.